We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

14 hedge funds and large institutions have $725K invested in Cyclo Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

12% less capital invested

Capital invested by funds: $820K → $725K (-$95.1K)

13% less funds holding

Funds holding: 16 → 14 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$61.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$22.7K
3
Northern Trust
Northern Trust
Illinois
+$21.2K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.29K
5
Osaic Holdings
Osaic Holdings
Arizona
+$5.11K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$507K
2
TRCT
Tower Research Capital (TRC)
New York
-$6.15K
3
Citadel Advisors
Citadel Advisors
Florida
-$1.94K
4
UBS Group
UBS Group
Switzerland
-$1.38K
5
SSG
Summit Securities Group
New York
-$1K

CYTH Hedge Fund Activity: Q2 2023 in Review

14 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q2 2023, worth a combined $725K — down 12% from $820K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CYTH and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $61.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $507K sold.

  • 14 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q2 2023, down from 16 in Q1 2023.
  • Funds reported $725K of Cyclo Therapeutics, Inc. Common Stock stock for Q2 2023, down 12% quarter-over-quarter.
  • 2 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q2 2023 and 4 closed out, a net change of -2 holders.
  • The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q2 2023 was Geode Capital Management, an estimated $61.4K added.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q2 2023 was Armistice Capital, an estimated $507K sold.

Based on aggregated 13F filings for Q2 2023.